Table 3.
Immunoglobulin (Ig)G1, IgG3 and IgG4 antibody levels to H1N1 and H3N2 before and 28 days after influenza vaccination in healthy controls (HC), rheumatoid arthritis (RA) patients treated with methotrexate (RA-MTX) or rituximab (RA-RTX)
| Mean ± s.d. (μg/ml) | Mean ± s.d. (μg/ml) | P-value | ||
|---|---|---|---|---|
| HC | T = 0 | T = 28 | ||
| IgG1 | A/H1N1 | 50·58 ± 86·15 | 97·23 ± 96·67 | <0·001 |
| A/H3N2 | 42·81 ± 59·84 | 97·04 ± 122·40 | <0·001 | |
| IgG3 | A/H1N1 | 0·348 ± 0·899 | 1·169 ± 2·137 | <0·001 |
| A/H3N2 | 0·350 ± 0·852 | 0·948 ± 1·929 | <0·001 | |
| IgG4 | A/H1N1 | 0·195 ± 0·492 | 0·234 ± 0·610 | 0·022 |
| A/H3N2 | 0·520 ± 1·573 | 0·578 ± 1·586 | n.s. | |
| RA-MTX | ||||
| IgG1 | A/H1N1 | 23·05 ± 17·99 | 83·00 ± 92·85 | 0·0001 |
| A/H3N2 | 17·30 ± 14·53 | 98·25 ± 169·3 | 0·0001 | |
| IgG3 | A/H1N1 | 0·134 ± 0·225 | 0·331 ± 0·440 | 0·0024 |
| A/H3N2 | 0·152 ± 0·205 | 0·484 ± 0·625 | 0·0015 | |
| IgG4 | A/H1N1 | 0·137 ± 0·217 | 0·221 ± 0·0396 | n.s. |
| A/H3N2 | 0·197 ± 0·297 | 0·256 ± 0·484 | n.s. | |
| RA-RTX | ||||
| IgG1 | A/H1N1 | 25·87 ± 20·27 | 59·87 ± 78·32 | 0·0053 |
| A/H3N2 | 25·39 ± 24·37 | 37·35 ± 43·90 | 0·0379 | |
| IgG3 | A/H1N1 | 0·215 ± 0·617 | 0·303 ± 0·841 | 0·0467 |
| A/H3N2 | 0·227 ± 0·561 | 0·296 ± 0·663 | n.s. | |
| IgG4 | A/H1N1 | 0·079 ± 0·166 | 0·074 ± 0·150 | n.s. |
| A/H3N2 | 0·095 ± 0·143 | 0·083 ± 0·164 | n.s. |
s.d. = standard deviation; n.s. = not significant.